Janus Kinase Inhibitor Market

Janus Kinase Inhibitor Market – Size, Share,
Outlook, and Opportunity Analysis, 2018 –
2026
Janus kinase (Jak) is a family of non-tyrosine receptor kinases, which play a major role in
cytokine signaling. Binding of cytokines (ligand) to receptor results in receptor dimerization and
ultimately activates Jak-mediated phosphorylation of the receptor. Jak phosphorylates STAT
(Signal Transducer and Activator of Transcription proteins) and STAT dimer carries out the
transcription of genes which are critical for signal cascade involved in inflammatory and
immune response. Therefore, Janus kinase is used as a target in treatment of autoimmune
disorders such as rheumatoid arthritis.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/2553
Janus Kinase Inhibitor Market Drivers
Jak inhibitors are increasingly preferred for industrial research due to their critical role in
immune response signaling. For instance, in June 2018, Eli Lilly and Company announced
approval from the U.S. Food and Drug Administration (FDA) for OLUMIANT (baricitinib) — an
oral medication for rheumatoid arthritis in adults. Approval was granted for use of baricitinib in
combination with methotrexate (MTX) or other disease-modifying antirheumatic drugs (DMARDs)
or as monotherapy. The drug inhibits activation of Jak1/2 (Janus kinase 1 and 2) and decreases
the production of inflammatory cytokines, thereby inhibiting inflammatory response. Therefore,
increasing launch of new drugs is expected to fuel the global janus kinase inhibitor market
growth over the forecast period.
Janus Kinase Inhibitor Market Regional Analysis
The Janus kinase pathway mediates intracellular signaling of over sixty cytokines. Dysregulation
of cytokines causes systemic lupus erythematosus (SLE) -- an autoimmune disorder and chronic
disease, which is characterized by inflammation of connective tissues such as cartilage and
blood vessel lining. According to National Center for Biotechnology Information (NCBI), the
highest prevalence and incidence of SLE was in recorded in North America (23.2/100 000
person) during the period August 2013- September 2016. Therefore, high prevalence of SLE is
expected to boost North America janus kinase inhibitor market growth over the forecast period.
Report includes chapters which deeply display the following deliverable about industry :
• Janus Kinase Inhibitor Market Research Objective and Assumption
• Janus Kinase Inhibitor Market Purview - Report Description, Executive Summary, and
Coherent Opportunity Map (COM)
• Janus Kinase Inhibitor Market Dynamics, Regulations, and Trends Analysis - Market Dynamics,
Regulatory Scenario, Industry Trend, Merger and Acquisitions, New system Launch/Approvals,
Value Chain Analysis, Porter’s Analysis, and PEST Analysis
• Global Janus Kinase Inhibitor Market, By Regions
• Janus Kinase Inhibitor Market Competition by Manufacturers including Production, Share,
Revenue, Average Price, Manufacturing Base Distribution, Sales Area and Product Type.
• Janus Kinase Inhibitor Market Manufacturers Profiles/Analysis including Company Basic
Information, Manufacturing Base and Its Competitors.
• Janus Kinase Inhibitor Market Manufacturing Cost Analysis including Key Raw Materials and
Key Suppliers of Raw Materials.
• Industrial Chain, Sourcing Strategy and Downstream Buyers including Upstream Raw Materials
Sourcing and Downstream Buyers
• Marketing Strategy Analysis, Distributors/Traders including Marketing Channel, Market
Positioning and Distributors/Traders List.
• Market Effect Factors Analysis including Technology Progress/Risk, Consumer Needs/Customer
Preference Change and Economic/Political Environmental Change.
• Janus Kinase Inhibitor Market Forecast including Production, Consumption, Import and Export
Forecast by Type, Applications and Region.
• Research Findings and Conclusion
Janus Kinase Inhibitor Market Key Players
Some of the key players operating in the global Janus kinase inhibitor market include, Eli Lilly
and Company, Astellas Pharma Inc., Pfizer Inc.,
Baxter International Inc., Novartis
International AG, Gilead Sciences Inc., Sierra Oncology, Inc., CTI BioPharma Corp., and Incyte
Corporation.
Request For Customization of Research Report @
https://www.coherentmarketinsights.com/insight/request-customization/2553
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering actionready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

Janus kinase (Jak) is a family of non-tyrosine receptor kinases, which play a major role in cytokine signaling.

Download Report